CAGE Bio Inc. joins BioLabs Pegasus Park in Dallas as the newest tenant, occupying a private lab suite. A clinical-stage startup, CAGE Bio Inc. is advancing a proprietary deep eutectic ionic liquid platform to develop novel therapies in dermatology, inflammation, and immunology.

“BioLabs at Pegasus Park offers an optimal setting for our mission to redefine the safety and efficacy standards in pharmaceuticals,” said Dr. Nitin Joshi, CEO of CAGE Bio Inc.

Pegasus Park is the regional epicenter for life sciences and biotechnology in North Texas. The campus convenes an ecosystem of companies, accelerators, investors, universities and talent.

BioLabs Pegasus Park offers 37,000 square feet of co-working and early-stage Class A laboratory and office space for start-up life science companies to perform research, collaborate with fellow scientists, incubate ideas, access investment capital and commercialize or license resulting intellectual property. Complementing the thriving startup community at BioLabs Pegasus Park, Bridge Labs at Pegasus Park provides 135,000 square feet of purpose-built research and development space to support the needs of life sciences companies after they become more established.

“Our focus is on developing innovative medicines that combine the effectiveness of systemic drugs with the safety of localized administration, including topicals, to treat serious immunological diseases like atopic dermatitis and vitiligo.”

The addition of CAGE Bio Inc. marks a significant milestone in BioLabs Pegasus Park’s continued growth and impact since its launch in 2022, further solidifying its role as a thriving hub for innovation in the life sciences.

For more information about Pegasus Park, please visit PegasusPark.com.